Skip to content
Norfloxacin
Chibroxin, Noroxin (norfloxacin) is a small molecule pharmaceutical. Norfloxacin was first approved as Noroxin on 1986-10-31. It is used to treat bacterial conjunctivitis, bacterial infections, cystitis, escherichia coli infections, and gonorrhea amongst others in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
eye diseasesD005128
urogenital diseasesD000091642
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Norfloxacin
Tradename
Company
Number
Date
Products
NOROXINMerck KGaAN-019384 DISCN1986-10-31
1 products, RLD
CHIBROXINMerck KGaAN-019757 DISCN1991-06-17
1 products
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
bacterial conjunctivitisEFO_1000829D003234H10.0
bacterial infections—D001424A49
cystitisEFO_1000025D003556N30
escherichia coli infectionsEFO_1001318D004927B96.20
gonorrheaDOID_7551D006069A54
haemophilus infectionsEFO_1001127D006192—
prostatitisEFO_0003830D011472N41
protozoan infections—D011528B50-B64
pseudomonas infectionsEFO_0001076D011552—
staphylococcal infections—D013203A49.01
Show 1 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
J: Antiinfectives for systemic use
— J01: Antibacterials for systemic use
— J01M: Quinolone antibacterials
— J01MA: Fluoroquinolone antibacterials, systemic
— J01MA06: Norfloxacin
— J01R: Combinations of antibacterials
— J01RA: Combinations of antibacterials
— J01RA13: Norfloxacin and tinidazole
— J01RA14: Norfloxacin and metronidazole
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01A: Antiinfective ophthalmologics
— S01AE: Fluoroquinolone antiinfectives, ophthalmologic
— S01AE02: Norfloxacin
HCPCS
No data
Clinical
Clinical Trials
9 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
GastritisD005756EFO_0000217K29.71——1—2
SchizophreniaD012559EFO_0000692F20———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Gastroesophageal refluxD005764EFO_0003948K21——1—12
HeartburnD006356R12——1——1
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—3————3
GastroparesisD018589EFO_1000948K31.841————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameNORFLOXACIN
INNnorfloxacin
Description
Norfloxacin is a quinolinemonocarboxylic acid with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase. It has a role as an antibacterial drug, a DNA synthesis inhibitor, a xenobiotic and an environmental contaminant. It is a quinolinemonocarboxylic acid, a N-arylpiperazine, a quinolone, a quinolone antibiotic and a fluoroquinolone antibiotic.
Classification
Small molecule
Drug classantibacterials (quinolone derivatives)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNCC3)cc21
Identifiers
PDB—
CAS-ID70458-96-7
RxCUI7517
ChEMBL IDCHEMBL9
ChEBI ID100246
PubChem CID4539
DrugBankDB01059
UNII IDN0F8P22L1P (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 12,612 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
843 adverse events reported
View more details